Reading the tape
NASDAQ: NVCT
Nuvectis Pharma, Inc.
Healthcare · Biotechnology
Market Cap
$243.92M
52w High
$11.15
52w Low
$5.55
P/E
-7.94
Volume
107.64K
Outstanding Shares
26.49M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: -5.18%FCF (TTM): -52.08%
What changed
The stock fell 5.18% over the last year. Free cash flow declined 52.08% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
CEORon Bentsur
SectorHealthcare
IndustryBiotechnology
Employees13
IPO dateFeb 4, 2022
Valuation
Forward P/E—
EV/EBITDA-4.83
Enterprise value$133.05M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-143.61%▲26.59%vs FY2024
Analyst consensus
RatingBuy
Target price$10.00▲8.61%
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$0.30 · Revenue est —
View